• Our Company

QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

For more information please visit www.quintilesims.com.

Driving Healthcare Performance in Slovenia

Established in Ljubljana in 1992, QuintilesIMS Slovenia offers wide range of solutions for the healthcare industry including wholesaler based market information, consulting services (Radar Dynamics, Pharmacy Segmentation and Targeting, Deep Dive Analysis, Launch Excellence...), databases of all health care professionals – One Key, CRM system MI Nexxus and Business Intelligence solutions.

Our data covers drugs on prescription, registered over-the-counter products, and unregistered products as well (cosmetics, nutritional products, patient care products…).

You can monitor your markets through advanced tools on your desktop or mobile devices on a monthly, weekly or even daily basis.

In 2016, the size of the pharmaceutical market in Slovenia (retail and hospital) reached €571 million EUR in 2016 (Ex-MNF price), increasing over 4% compared to the previous year. The leading therapy area in this period was L Antineoplast+Immunomodul, with 12,12 % increase compared to the previous year. The leading segment within Over-the-counter market has been segment Cough Cold and other respiratory remedies, with 14,8 million EUR value in 2016.

180 corporations currently operate in the Slovenian pharmaceutical market (Rx) with ten accounting for 58 % of total market sales in 2016.